MX2009010051A - Anticuerpos anti-esclereostina. - Google Patents

Anticuerpos anti-esclereostina.

Info

Publication number
MX2009010051A
MX2009010051A MX2009010051A MX2009010051A MX2009010051A MX 2009010051 A MX2009010051 A MX 2009010051A MX 2009010051 A MX2009010051 A MX 2009010051A MX 2009010051 A MX2009010051 A MX 2009010051A MX 2009010051 A MX2009010051 A MX 2009010051A
Authority
MX
Mexico
Prior art keywords
antibodies
bone
sclerostin antibodies
sclerostin
osteoporosis
Prior art date
Application number
MX2009010051A
Other languages
English (en)
Inventor
David Matthew Marquis
Andrew Ihor Korytko
Eric Michael Smith
Barbara Anne Swanson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2009010051A publication Critical patent/MX2009010051A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos humanizados y quiméricos que enlazan específicamente esclerostina humana y son caracterizados por tener propiedades neutralizantes fuertes y alta afinidad. Los anticuerpos de la invención son útiles para incrementar la masa ósea, densidad mineral ósea y consistencia ósea, para el tratamiento de varios trastornos, por ejemplo, osteoporosis, en un sujeto humano.
MX2009010051A 2007-03-20 2008-03-11 Anticuerpos anti-esclereostina. MX2009010051A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89581307P 2007-03-20 2007-03-20
PCT/US2008/056527 WO2008115732A2 (en) 2007-03-20 2008-03-11 Anti-sclerostin antibodies

Publications (1)

Publication Number Publication Date
MX2009010051A true MX2009010051A (es) 2009-10-12

Family

ID=39756356

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010051A MX2009010051A (es) 2007-03-20 2008-03-11 Anticuerpos anti-esclereostina.

Country Status (32)

Country Link
US (3) US7744874B2 (es)
EP (2) EP2664346A1 (es)
JP (2) JP2010524846A (es)
KR (1) KR101123487B1 (es)
CN (1) CN101646457B (es)
AU (1) AU2008229141B2 (es)
BR (1) BRPI0809026A2 (es)
CA (1) CA2682212C (es)
CO (1) CO6230999A2 (es)
CR (1) CR11004A (es)
CY (1) CY1114784T1 (es)
DK (1) DK2131860T3 (es)
DO (1) DOP2009000223A (es)
EA (1) EA018204B1 (es)
EC (1) ECSP099658A (es)
ES (1) ES2446293T3 (es)
HK (1) HK1138790A1 (es)
HR (1) HRP20140108T1 (es)
IL (1) IL200437A0 (es)
MA (1) MA31308B1 (es)
MX (1) MX2009010051A (es)
MY (1) MY149129A (es)
NZ (1) NZ578870A (es)
PL (1) PL2131860T3 (es)
PT (1) PT2131860E (es)
RS (1) RS53157B (es)
SI (1) SI2131860T1 (es)
SV (1) SV2009003374A (es)
TN (1) TN2009000383A1 (es)
UA (1) UA96474C2 (es)
WO (1) WO2008115732A2 (es)
ZA (1) ZA200906345B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101469329B (zh) 1998-11-27 2012-10-24 达尔文发现有限公司 增加骨矿化的组合物和方法
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP3345607B1 (en) 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
BRPI0809026A2 (pt) * 2007-03-20 2014-09-23 Lilly Co Eli Anticorpos antiesclerotina
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
US20110044978A1 (en) * 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
RU2012147249A (ru) 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
AU2011239935A1 (en) 2010-04-16 2012-11-08 Novartis Ag Methods and compositions for improving implant osseointegration
BR112012028920B1 (pt) 2010-05-14 2021-03-23 Amgen Inc. Formulações líquidas estéreis de anticorpo de alta concentração e método para reduzir a viscosidade de uma formulação de proteína
US8834883B2 (en) 2010-06-14 2014-09-16 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
EP3757126A1 (en) 2010-11-05 2020-12-30 Novartis AG Methods of treating psoriatic arthritis using il-17 antagonists
JP5319651B2 (ja) * 2010-11-18 2013-10-16 日本電信電話株式会社 分析方法
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
US9217040B2 (en) 2011-01-14 2015-12-22 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
SG193610A1 (en) 2011-03-25 2013-11-29 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
PL3404041T3 (pl) 2011-04-19 2020-12-14 Amgen Inc. Sposób leczenia osteoporozy
WO2012149246A1 (en) 2011-04-29 2012-11-01 Novartis Ag Methods of treating squamous cell carcinoma related applications
HUE039786T2 (hu) 2011-08-04 2019-02-28 Amgen Inc Csonthiány-defektusok kezelési módszere
US9803009B2 (en) 2011-10-24 2017-10-31 Abbvie Inc. Immunobinders directed against TNF
CN104203978A (zh) * 2011-10-24 2014-12-10 艾伯维股份有限公司 针对硬化蛋白的免疫结合剂
UY34410A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoligantes biespecificos dirigidos contra tnf
SG11201403718YA (en) 2011-12-28 2014-07-30 Amgen Inc Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
AU2013285488B2 (en) * 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US20140065144A1 (en) * 2012-08-30 2014-03-06 National Cheng Kung University Use of il-20 antagonists for promoting bone fracture healing
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
JOP20140049B1 (ar) * 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
BR112017014258A2 (pt) * 2014-12-30 2018-03-06 Celgene Corp anticorpos anti-cd47 e usos dos mesmos
RS61158B1 (sr) * 2015-03-13 2021-01-29 Jiangsu Hengrui Medicine Co Anti-sklerostin antitelo, antigen vezujući fragment i njegova medicinska upotreba
CA3015619A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3496744A1 (en) 2016-08-08 2019-06-19 Amgen Inc. Method of improving connective tissue attachment using anti-sclerostin antibodies
CN109890845B (zh) * 2016-10-28 2022-07-01 伊莱利利公司 抗rankl抗体及其用途
EP3534950A4 (en) * 2016-11-01 2020-05-06 AnaptysBio, Inc. ANTIBODIES AGAINST PROGRAMMED DEATH-1 (PD-1)
BR112019012731A2 (pt) * 2016-12-21 2019-11-26 Mereo Biopharma 3 Ltd uso de anticorpos antiesclerostina no tratamento de osteogênese imperfeita
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
EP3574010A4 (en) * 2017-01-30 2020-12-16 Chugai Seiyaku Kabushiki Kaisha ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE
US11530240B2 (en) 2017-06-09 2022-12-20 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
TW201909913A (zh) 2017-07-27 2019-03-16 大陸商江蘇恆瑞醫藥股份有限公司 一種ｓｏｓｔ抗體醫藥組成物及其用途
MX2020010092A (es) 2018-03-30 2020-10-28 Amgen Inc Variantes de anticuerpo c-terminales.
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
CN112702991A (zh) 2018-08-10 2021-04-23 安进公司 制备抗体药物配制品的方法
CN113784987A (zh) * 2019-01-22 2021-12-10 美国政府(由卫生和人类服务部的部长所代表) 靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
US20220275073A1 (en) 2019-08-12 2022-09-01 Amgen Inc. Anti-Sclerostin Antibody Formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CN101469329B (zh) * 1998-11-27 2012-10-24 达尔文发现有限公司 增加骨矿化的组合物和方法
US20040132021A1 (en) 2000-06-19 2004-07-08 Wendy Balemans Osteolevin gene polymorphisms
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
WO2004047609A2 (en) * 2002-11-27 2004-06-10 Visiopharm Aps A method and a system for establishing a quantity measure for joint destruction
EA015166B1 (ru) * 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
WO2005005604A2 (en) 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2006046935A1 (en) 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc Methods of optimizing antibody variable region binding affinity
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
BRPI0809026A2 (pt) * 2007-03-20 2014-09-23 Lilly Co Eli Anticorpos antiesclerotina

Also Published As

Publication number Publication date
CY1114784T1 (el) 2016-12-14
EP2664346A1 (en) 2013-11-20
IL200437A0 (en) 2010-04-29
RS53157B (en) 2014-06-30
KR101123487B1 (ko) 2012-03-23
JP2010524846A (ja) 2010-07-22
HK1138790A1 (en) 2010-09-03
US20110250205A1 (en) 2011-10-13
US20090060924A1 (en) 2009-03-05
DK2131860T3 (da) 2014-01-13
EA018204B1 (ru) 2013-06-28
US8257704B2 (en) 2012-09-04
PL2131860T3 (pl) 2014-05-30
CN101646457B (zh) 2013-05-01
CO6230999A2 (es) 2010-12-20
HRP20140108T1 (hr) 2014-02-28
TN2009000383A1 (en) 2010-12-31
AU2008229141B2 (en) 2013-02-07
UA96474C2 (en) 2011-11-10
AU2008229141A1 (en) 2008-09-25
US20100221263A1 (en) 2010-09-02
MY149129A (en) 2013-07-15
NZ578870A (en) 2012-01-12
EP2131860B1 (en) 2013-12-18
CA2682212C (en) 2014-05-06
ZA200906345B (en) 2010-11-24
US7988970B2 (en) 2011-08-02
US7744874B2 (en) 2010-06-29
EA200970874A1 (ru) 2010-02-26
ECSP099658A (es) 2009-10-30
CN101646457A (zh) 2010-02-10
SI2131860T1 (sl) 2014-02-28
JP2013151504A (ja) 2013-08-08
MA31308B1 (fr) 2010-04-01
JP5758933B2 (ja) 2015-08-05
BRPI0809026A2 (pt) 2014-09-23
CA2682212A1 (en) 2008-09-25
ES2446293T3 (es) 2014-03-07
CR11004A (es) 2009-11-02
SV2009003374A (es) 2011-01-10
PT2131860E (pt) 2014-03-04
WO2008115732A2 (en) 2008-09-25
WO2008115732A3 (en) 2008-12-11
DOP2009000223A (es) 2009-10-15
KR20090114462A (ko) 2009-11-03
EP2131860A2 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
MY149129A (en) Anti-sclerostin antibodies
WO2007047112A3 (en) Anti-myostatin antibodies
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
TW200736275A (en) Methods and compositions for treating allergic diseases
TN2011000463A1 (en) Composition and methods for increasing muscle growth
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
TN2009000529A1 (en) Methods and compositions for treating allergic diseases
WO2007042309A3 (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
MX2010008688A (es) Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
MX2012004084A (es) Anticuerpos siglec-15 para tratar enfermedad relacionada con perdida osea.
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
WO2008030706A3 (en) Anti-myostatin antibodies
MX2009003774A (es) Anticuerpos para linfotoxina-alfa.
MY158481A (en) Compositions and methods for treating inflammatory disorders
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
WO2008042435A3 (en) Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same
UA102683C2 (ru) Антитело, направленное против ангиопоэтина-1 и ангиопоэтина-2, и его применение
UA94245C2 (en) Anti-il-17 antibodies
UA102437C2 (ru) Композиции и способы для усиления мышечного роста

Legal Events

Date Code Title Description
FG Grant or registration